The Opportunity

  • Molecular technology, 15 years ago, completely displaced culture-based methods for diagnosing viral infections, transforming patient outcomes through improvements in speed (days to hours) and accuracy.
  • Despite the potential 50x speed advantage, molecular technologies have failed to supplant blood culture in the $3B Blood Stream Infection (BSI) diagnostic market.
  • This is due to the poor sensitivity of existing diagnostic platforms
  • Tangen has solved this by developing a platform that is extremely sensitive, rapid, economical, and also simple to use.